Vascepa's Effect on Triglycerides with Statins
Vascepa (icosapent ethyl), a purified EPA omega-3, reduces triglycerides by 18-45% in patients on statins with elevated levels (≥150 mg/dL). In the REDUCE-IT trial, patients on statins plus Vascepa saw median triglycerides drop 19% from baseline versus 4% on statins plus placebo.[1][2]
Impact on Cardiovascular Events
Vascepa boosts statin efficacy primarily by cutting major adverse cardiovascular events (MACE). REDUCE-IT showed a 25% relative risk reduction in MACE (25% CV death, nonfatal MI, stroke, revascularization, or unstable angina) for statin users on Vascepa versus placebo. Absolute risk dropped from 19.4% to 14.8% over 4.9 years.[1][3] This held across subgroups with varying statin doses or LDL levels.
How It Complements Statins' LDL Focus
Statins lower LDL cholesterol and modestly reduce triglycerides (10-30%), but leave residual CV risk in high-triglyceride patients. Vascepa targets triglycerides and inflammation without raising LDL, adding independent benefit. Meta-analyses confirm 20-30% MACE reduction when combined with statins.[4]
Who Benefits Most
Patients with triglycerides 135-499 mg/dL despite optimized statin therapy (per FDA label) see the strongest gains. No added benefit in those with triglycerides <150 mg/dL or uncontrolled LDL.[1][5] Real-world data (EVOLUTION trial) mirrors REDUCE-IT with 30% MACE reduction.[6]
Cost and Access Considerations
Vascepa costs $300-400/month without insurance; generics unlikely until patent expiry around 2030.[7] Covered by most plans for indicated patients, but prior authorization often required.
[1]: NEJM - REDUCE-IT Trial
[2]: FDA Vascepa Label
[3]: AHA Circulation - REDUCE-IT Analysis
[4]: JAMA Cardiology Meta-Analysis
[5]: Amarin REDUCE-IT Subgroup Data
[6]: JACC EVOLUTION Study
[7]: DrugPatentWatch - Vascepa